A biophysical perspective on the unexplored mechanisms driving Parkinson’s disease by amphetamine-like stimulants

Related Articles:

• A biophysical perspective on the unexplored mechanisms driving Parkinson's disease by amphetamine-like stimulants April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2213-2214. doi: 10.4103/1673-5374.310675.NO ABSTRACTPMID:33818498 | DOI:10.4103/1673-5374.310675
• A biophysical perspective on the unexplored mechanisms driving Parkinson's disease by amphetamine-like stimulants April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2213-2214. doi: 10.4103/1673-5374.310675.NO ABSTRACTPMID:33818498 | DOI:10.4103/1673-5374.310675
• Am I being unreasonable? November 16, 2018 Friday 16 November 2018If you’re feeling a bit down and need a quick pick-me-up, you could do worse than browse the discussion threads on mumsnet for a while.I’m not talking about the posts on pregnancy or breast feeding or dealing with toddlers. I’m talking about the “other” section. The most popular category on mumsnet is AIBU, for Am I Being…
• Driving Under the Influence of Parkinson’s May 6, 2017 “Have you ever noticed that anybody driving slower than you is an idiot, and anyone going faster than you is a maniac?” George Carlin “If all the cars in the United States were placed end to end, it would probably be Labor Day Weekend.” Doug Larson The Dilemma: At some age in our life, maybe, just maybe, we could lose…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly research review – March 2021 March 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2021. The post is divided into ten parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2299-2309. doi: 10.4103/1673-5374.309843.ABSTRACTNeuroprotective drugs and selective monoamine oxidase inhibitors can slow down the progression and improve symptoms of Parkinson's disease (PD). Since there is an implication of oxidative stress in the pathophysiological mechanisms of the disease, the compounds possessing an ability to reduce the oxidative stress are prime candidates for neuroprotection. Thereby our current study is…
• Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2299-2309. doi: 10.4103/1673-5374.309843.ABSTRACTNeuroprotective drugs and selective monoamine oxidase inhibitors can slow down the progression and improve symptoms of Parkinson's disease (PD). Since there is an implication of oxidative stress in the pathophysiological mechanisms of the disease, the compounds possessing an ability to reduce the oxidative stress are prime candidates for neuroprotection. Thereby our current study is…
• Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2299-2309. doi: 10.4103/1673-5374.309843.ABSTRACTNeuroprotective drugs and selective monoamine oxidase inhibitors can slow down the progression and improve symptoms of Parkinson's disease (PD). Since there is an implication of oxidative stress in the pathophysiological mechanisms of the disease, the compounds possessing an ability to reduce the oxidative stress are prime candidates for neuroprotection. Thereby our current study is…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Cognitive Impairment Is Best Predictor of Poor Driving by Patients December 8, 2020 A poor performance, due to cognitive impairments, on the Rookwood Driving Battery (RDB) — a set of tests aiming to evaluate specific neuropsychological skills that are important for safe vehicle operation — is the best predictor of poor driving among patients with Parkinson’s disease, a study has found. Apart from RDB performance, researchers found that people who were older, and…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• Alpha-synuclein preformed fibrils: a tool to understand Parkinson's disease and develop disease modifying therapy April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2219-2221. doi: 10.4103/1673-5374.310686.NO ABSTRACTPMID:33818501 | DOI:10.4103/1673-5374.310686
• Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2184-2197. doi: 10.4103/1673-5374.310608.ABSTRACTCorticotropin-releasing hormone is a critical component of the hypothalamic-pituitary-adrenal axis, which plays a major role in the body's immune response to stress. Mast cells are both sensors and effectors in the interaction between the nervous and immune systems. As first responders to stress, mast cells can initiate, amplify and prolong neuroimmune responses upon activation.…
• Alpha-synuclein preformed fibrils: a tool to understand Parkinson's disease and develop disease modifying therapy April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2219-2221. doi: 10.4103/1673-5374.310686.NO ABSTRACTPMID:33818501 | DOI:10.4103/1673-5374.310686
• Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2184-2197. doi: 10.4103/1673-5374.310608.ABSTRACTCorticotropin-releasing hormone is a critical component of the hypothalamic-pituitary-adrenal axis, which plays a major role in the body's immune response to stress. Mast cells are both sensors and effectors in the interaction between the nervous and immune systems. As first responders to stress, mast cells can initiate, amplify and prolong neuroimmune responses upon activation.…
• Alpha-synuclein preformed fibrils: a tool to understand Parkinson's disease and develop disease modifying therapy April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2219-2221. doi: 10.4103/1673-5374.310686.NO ABSTRACTPMID:33818501 | DOI:10.4103/1673-5374.310686
• Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2184-2197. doi: 10.4103/1673-5374.310608.ABSTRACTCorticotropin-releasing hormone is a critical component of the hypothalamic-pituitary-adrenal axis, which plays a major role in the body's immune response to stress. Mast cells are both sensors and effectors in the interaction between the nervous and immune systems. As first responders to stress, mast cells can initiate, amplify and prolong neuroimmune responses upon activation.…
• Exploring the contribution of the mitochondrial disulfide relay system to Parkinson's disease: the PINK1/CHCHD4 interplay April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2222-2224. doi: 10.4103/1673-5374.310679.NO ABSTRACTPMID:33818502 | DOI:10.4103/1673-5374.310679
• Exploring the contribution of the mitochondrial disulfide relay system to Parkinson's disease: the PINK1/CHCHD4 interplay April 5, 2021 Neural Regen Res. 2021 Nov;16(11):2222-2224. doi: 10.4103/1673-5374.310679.NO ABSTRACTPMID:33818502 | DOI:10.4103/1673-5374.310679